- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05029297
Study With Two Capsaicin Topic Treatments in Diabetic Neuropathy.
Study of Efficacy and Non-inferiority, With Two Capsaicin Topic Treatments, for the Moderate to Severe Pain in Diabetic Neuropathy.
Study Overview
Detailed Description
The sponsor created a new pharmaceutical formulation of CAPSAICIN topical solution applicable in roll-on. This new formulation in roll-on represents a line extension of drug ARAFARMADOL 0.075 cream, which is currently marketed in Spain by the sponsor.
The proposed investigational product as topical solution applicable in roll-on is expected to solve the compliance and safety issues of the cream with the same indications for use.
Eligible patients will be randomized into two groups: CAPSAICIN topical solution applicable in roll-on and CAPSAICIN cream (ARAFARMADOL® ) for 8 weeks. Then, they will have a 4 week washout period and will be crossed over to the other treatment group for 8 weeks. A follow-up period of 2 weeks will take place after the end of both treatments.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written or oral informed consent with witnesses, before initiating the specific procedures of the protocol.
- Non-pregnant, non-lactating man or woman ≥ 18 years.
- Patients diagnosed with Type I or II Diabetes Mellitus, treated or untreated.
- Patients with a diagnosis of painful peripheral diabetic neuropathy, treated or not treated
- Painful diabetic neuropathy of at least 3 months of evolution with moderate to severe pain ≥ 4 on the VAS scale in the selection phase.
- The pain must have been experienced daily, interfered with daily activities or sleep, and not attributable to psychological origin.
- Stabilization of pain medication at least during the month prior to the start of treatment. The patient must be prepared to remain in treatment with the same pain medications at the same doses as previous to the start, during the study and in the follow-up phase (24 weeks).
- Intact, non-irritated and dry skin in the painful areas to be treated.
- Patients with the ability to collaborate in the trial.
Exclusion Criteria:
- Allergic reactions to capsaicin.
- Patients with neuropathic pain of an etiology other than diabetes.
- Patients with peripheral ischemic pain due to diabetic artery disease.
- Patients with unstable glycemic control (glycosylated Hb ≥ 10.5%).
- Amputation of any part of the lower limb.
- Surgery scheduled during the clinical trial.
- Mild painful diabetic neuropathy (<4 VAS).
Other serious pathologies:
- Documented congestive heart failure or systolic dysfunction (LVEF ≤ 50%).
- Previous history of myocardial infarction in the 6 months prior to enrollment.
- Uncontrolled hypertension (160/110 mmHg maximum).
- Uncontrolled high-risk arrhythmias.
- Significant neurological or psychiatric disorders, including psychotic disorders, dementia that prevent patients from understanding and giving informed consent.
- Active uncontrolled infection.
- Use other topical pain medications in painful areas.
- History or current problem of substance abuse.
- Pregnant or lactating women. Women of childbearing potential should use effective contraception.
- Participation in another clinical trial with any non-marketed investigational drug during the 90 days prior to inclusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CAPSAICIN 0.75 mg/g topical solution applicable in roll-on
CAPSAICIN 0.75 mg / g topical solution applicable in roll-on: 4 applications per day for 8 weeks.
|
|
Active Comparator: CAPSAICIN 0.075% cream
CAPSAICIN 0.075% cream (ARAFARMADOL® 0.075% cream): 4 applications per day for 8 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To demonstrate the efficacy and the non-inferiority of a new formulation of the capsaicin topical solution in "roll-on" compared to capsaicin in cream.
Time Frame: Baseline to 8 weeks
|
To demonstrate the efficacy and the non-inferiority of a new formulation of Capsaicin 0.75 mg / g topical solution applicable in "roll-on" compared to the formulation currently marketed (comparator) in cream (Arafarmadol® 0.075% cream).
The main variable will be the decrease in pain on the visual analogue pain scale (score range from 0 (no pain) to 10 (worst pain possible) at 8 weeks of treatment with each drug.
The change in efficacy between the two treatments (pain reduction with cream minus pain reduction with roll-on) will be calculated and the 95% confidence interval for this change will be obtained; If the confidence interval does not exceed the non-inferiority limit (1.0), it will be concluded that the new formulation is not inferior to the one currently marketed.
|
Baseline to 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Adverse Events (AEs) and Serious Adverse Events (SAEs) between both treatment groups.
Time Frame: From Visit 1, and at each visit, up to 22 weeks.
|
All AEs will be recorded, whether considered minor or serious, drug-related or not.
|
From Visit 1, and at each visit, up to 22 weeks.
|
Change from baseline in both treatment groups of QoL.
Time Frame: Baseline to 8 weeks
|
The EQ-5D consists of 2 parts - the descriptive part and the visual scale analog (EVA).
The EQ-5D descriptive system comprises 5 dimensions: mobility, self-care, habitual activities, pain / discomfort, and anxiety / depression.
In the EVA the patient scores their health between two extremes, 0 and 100, worst and best health status imaginable.
|
Baseline to 8 weeks
|
Treatment compliance in both treatment groups.
Time Frame: At the end of each treatment phase (8th week).
|
Treatment compliance is measured by the use of Morisky-Green test.
|
At the end of each treatment phase (8th week).
|
Change from baseline in both treatment groups of height.
Time Frame: Baseline to every 4 weeks up to 22 weeks.
|
Height measured by cm.
|
Baseline to every 4 weeks up to 22 weeks.
|
Change from baseline in both treatment groups of weight.
Time Frame: Baseline to every 4 weeks up to 22 weeks.
|
Weight measured by kg.
|
Baseline to every 4 weeks up to 22 weeks.
|
Change from baseline in both treatment groups of blood pressure.
Time Frame: Baseline to every 4 weeks up to 22 weeks.
|
Blood pressure measured by mm Hg.
|
Baseline to every 4 weeks up to 22 weeks.
|
Change from baseline in both treatment groups of dermatological assessment of the painful area.
Time Frame: Baseline to 8 weeks.
|
Dermatological assessment is measured by Dermatological Assessment Scale (scale range from 0 (without causing irritation) to 7 (important reaction that extends beyond the assessed area).
|
Baseline to 8 weeks.
|
Grade of compliance/complacency of treatment.
Time Frame: Last Follow-Up visit of the study (22nd week).
|
A patient compliance questionnaire (6 questions) will be self-administered to the patient and must be completed during the follow-up visit.
|
Last Follow-Up visit of the study (22nd week).
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Dr. Raffaelle Carraro, Hospital Universitario La Princesa. Madrid. Investigator Site Coordinator.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Endocrine System Diseases
- Diabetes Complications
- Diabetes Mellitus
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Diabetic Neuropathies
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Sensory System Agents
- Dermatologic Agents
- Antipruritics
- Capsaicin
Other Study ID Numbers
- ITHUEC-CAP/10-5
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Neuropathy, Painful
-
Helixmith Co., Ltd.CompletedDiabetic Neuropathy, Painful | Painful Diabetic NeuropathyUnited States
-
Helixmith Co., Ltd.CompletedDiabetic Neuropathy, Painful | Painful Diabetic NeuropathyUnited States
-
WinSanTor, IncCompletedPeripheral Neuropathy | Painful Diabetic Neuropathy | Diabetic Neuropathies, PainfulCanada
-
Maastricht University Medical CenterCompletedPainful Diabetic Neuropathy | Diabetic Neuropathies, Painful | Neuralgia, DiabeticNetherlands
-
University of PlymouthNot yet recruitingDiabetic Peripheral Neuropathy | Painful Diabetic Neuropathy
-
Nevro CorpRecruitingPainful Diabetic NeuropathyUnited States
-
Dartmouth-Hitchcock Medical CenterRecruitingPainful Diabetic NeuropathyUnited States
-
Duta Wacana Christian UniversityPT SOHO Global Health TbkUnknownPainful Diabetic NeuropathyIndonesia
-
Helixmith Co., Ltd.Completed
-
BioDelivery Sciences InternationalCompletedNeuropathy | Painful Diabetic Neuropathy | Diabetic NeuropathyUnited States
Clinical Trials on Capsaicin
-
University of FloridaCompletedPain | FibromyalgiaUnited States
-
Nantes University HospitalRecruitingNeuropathic Pain | Coccyx Disorder | CoccygodyniaFrance
-
University of FloridaCompleted
-
NeurogesXCompletedHIV Infections | Pain | Peripheral Nervous System Diseases
-
Samyang Biopharmaceuticals CorporationCompletedPostherpetic Neuralgia | Peripheral Nerve InjuryKorea, Republic of
-
Hospital de MataróInstituto de Salud Carlos III; Consorci Sanitari del MaresmeRecruitingStroke | Oropharyngeal Dysphagia | Swallowing Disorder | Stroke, ComplicationSpain
-
The University of Texas Health Science Center,...University of California, San FranciscoActive, not recruitingMigraine | Cluster Headache | Trigeminal Autonomic Cephalgia | Hemicrania Continua | Paroxysmal Hemicrania | SUNCT | Short-Lasting Unilateral Neuralgiform Headache With Conjunctival Injection and TearingUnited States
-
Propella TherapeuticsCompletedPain | Osteoarthritis, KneeUnited States
-
Averitas Pharma, Inc.RecruitingPost Surgical Neuropathic PainUnited States, Spain, France, Netherlands, Poland, United Kingdom
-
Carilion ClinicChorda Pharma, Inc.Completed